Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01539629 · ClinicalTrials.gov registry record

ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0

A clinical trial, sponsored by Boston Scientific Corporation.

Completed
Registry status
50
Enrollment target

NCT01539629: Completed study, sponsored by Boston Scientific Corporation.

NCT01539629 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01539629 has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
50 participants
Enrollment target

Study Summary

This 3rd phase of the ELEVATE study. The study is collecting data from an implanted CRT-D device to evaluate a new feature for future heart failure devices.

Primary Outcome

The primary objective of this study is to collect real-time signals during LV pacing and voltage step-down from patients with implanted COGNIS devices.

Interventions

  • DEVICE Cardiac pacing

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2012-03
Est. Completion 2012-11
Boston Scientific Corporation

280 total trials

What the finished NCT01539629 record still lists

NCT01539629 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Cardiac pacing is the first listed.

NCT01539629 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01539629 about?

NCT01539629 is a clinical study titled "ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0". This 3rd phase of the ELEVATE study. The study is collecting data from an implanted CRT-D device to evaluate a new feature for future heart failure devices.

What is the current status of trial NCT01539629?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2012-03. Estimated completion is 2012-11.

What interventions are being tested in trial NCT01539629?

The interventions under investigation include: Cardiac pacing (DEVICE).

Who is sponsoring clinical trial NCT01539629?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01539629, the US trial registry maintained by the National Library of Medicine. NCT01539629 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.